Interleukin-6 in neuro-Behcet's disease: Association with disease subsets and long-term outcome

被引:99
|
作者
Akman-Demir, Guelsen [1 ]
Tuezuen, Erdem [1 ]
Icoez, Sema [1 ]
Yesilot, Niluefer [1 ]
Yentuer, Sibel P. [2 ]
Kuertuencue, Murat [1 ]
Mutlu, Melike [1 ]
Saruhan-Direskeneli, Gueher [2 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Neurol, TR-34390 Istanbul, Turkey
[2] Istanbul Univ, Istanbul Fac Med, Dept Physiol, TR-34390 Istanbul, Turkey
关键词
Behcet's disease; Neuro-Behcet's disease; Interleukin-6; Cerebrospinal fluid; Outcome;
D O I
10.1016/j.cyto.2008.10.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Increased cerebrospinal fluid (CSF) IL-6 has been reported in patients with Behcet's disease (BD) and neurological involvement. To elucidate the value of IL-6 as a marker of disease activity, serum and CSF IL-6 levels of 68 BD patients with acute (26) or chronic progressive (14) parenchymal involvement (pNB), dural sinus thrombosis (10), ischemic stroke (5) or headache (13) were measured by ELISA. Samples from multiple sclerosis, subacute sclerosing panencephalitis, and noninflammatory neurological disorders were used as controls. CSF but not serum samples of neuro-BD patients with acute pNB displayed significantly increased IL-6 levels as compared to other groups. Chronic progressive pNB patients also showed increased CSF IL-6 levels, albeit less prominent. Patients with increased CSF IL-6 levels were more likely to have increased CSF cell counts and total protein levels and these three parameters were correlated with long-term (>= 3 years) disease outcome. In four chronic progressive patients. IL-6 was elevated despite otherwise normal CSF. CSF IL-6 seems to be a marker of disease activity and long-term outcome for pNB along with CSF cell count and protein levels. CSF IL-6 could be used in chronic progressive patients who have normal CSF cell, or protein levels to detect disease activity. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:373 / 376
页数:4
相关论文
共 50 条
  • [31] GABA and microbiota association in multiple sclerosis and neuro-Behcet's disease
    Oezguen, N.
    Yalcinkaya, N.
    Kucukali, C. I.
    Dahdouli, M.
    Hollister-Branton, E.
    Luna, R. A.
    Turkoglu, R.
    Kurtuncu, M.
    Eraksoy, M.
    Savidge, T.
    Tuzun, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 656 - 656
  • [32] Sexual dysfunction in Neuro-Behcet's disease
    Sorgun, Mine Hayriye
    Kuzu, Muge
    Erdogan, Seyda
    Yucesan, Canan
    JOURNAL OF CLINICAL NEUROSCIENCE, 2020, 78 : 211 - 214
  • [33] Kleptomania in Patients with Neuro-Behcet's Disease
    Shugaiv, Erkingul
    Kiyat-Atamer, Asli
    Tuzun, Erdem
    Kurtuncu, Murat
    Baral-Kulaksizoglu, Isin
    Demir, Gulsen Akman
    MEDICAL PRINCIPLES AND PRACTICE, 2013, 22 (06) : 550 - 554
  • [34] MRI findings of neuro-Behcet’s disease
    Afshin Borhani Haghighi
    Sirous Sarhadi
    Siamak Farahangiz
    Clinical Rheumatology, 2011, 30 : 765 - 770
  • [35] A CASE OF PROBABLE NEURO-BEHCET'S DISEASE
    Simoni, Michela
    Wright, Benjamin
    Wysota, Barbara
    Sivaguru, Arul
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2017, 88 : A76 - A76
  • [36] Neuro-Behcet's disease: a case report
    Gabrielyan, I.
    Harutyunyan, K.
    Avagyan, G.
    Amirjanyan, H.
    Khachaturyan, S.
    Hambardzumyan, H.
    Manvelyan, H. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 510 - 510
  • [37] Treatment of neuro-Behcet's disease: an update
    Haghighi, Afshin Borhani
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (04) : 565 - 574
  • [38] Neuro-Behcet's disease in Japan - Reply
    Devlin, T
    Gray, L
    Allen, NB
    Friedman, AH
    Tien, R
    Morgenlander, JC
    NEUROLOGY, 1996, 47 (02) : 614 - 615
  • [39] MRI findings of neuro-Behcet's disease
    Haghighi, Afshin Borhani
    Sarhadi, Sirous
    Farahangiz, Siamak
    CLINICAL RHEUMATOLOGY, 2011, 30 (06) : 765 - 770
  • [40] MRI findings in neuro-Behcet's disease
    Lee, SH
    Yoon, PH
    Park, SJ
    Kim, DI
    CLINICAL RADIOLOGY, 2001, 56 (06) : 485 - 494